BRF116056 is the first clinical experience with GSK2118436, a BRAF inhibitor, in Japan. This study will be designed to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 in Japanese subjects with BRAF V600 mutation positive solid tumors using continuous daily dosing schedule.
Name: GSK2118436Description: Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.Type: Drug
Dose Escalation Part
Description: Adverse Events will be graded by the investigator according to the NCI-CTCAE (version 4.0)Measure: Number of participants with adverse events as a measure of safety and tolerability Time: First 28 days for Dose-limiting toxicity, Adverse Events for 1 year
Single Group Assignment
There is one SNP
- Subjects must have BRAF V600E or K mutant positive tumors. --- V600E ---